Compare Cytokinetics Inc (CYTK) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VF Corp — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while VF Corp trades at $14.78 (market cap $5.86B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and VF Corp pays a 2.42% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | VFC | |
|---|---|---|
Market Cap | $10.78B | $5.86B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $21.55 |
52-Week Low | $34.31 | $12.21 |
Enterprise Value | $10.88B | $10.14B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
VFC trades at $14.99, up 1.63% on the day, with a bearish technical signal and mixed earnings. Recent Q1 2027 results missed EPS estimates, though revenue exceeded expectations. The company faces challenges with Vans brand performance and a CFO transition, but maintains a raised fiscal 2027 sales outlook. Cash flow trends show improvement in 2026, with net cash flow turning positive.
Outlook remains cautious due to weak consumer sentiment and brand-specific headwinds, but deleveraging progress and margin gains offer potential upside. Risks include persistent Vans drag and macro pressures. Analyst consensus is Hold with a $17.44 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
